Physician profile
Vincent Calderon
NPI 1972508513
$935.49
in general payments reported to CMS, 2019-2025
22 companies · $34.86 in 2025
The $34.86 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $37.40 · 2021: $179 · 2022: $147 · 2023: $195 · 2024: $146 · 2025: $34.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $375.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $208.13 | 2019-2024 | Vaxelis, Gardasil 9, Gardasil |
| Abbott Laboratories | $115.97 | 2023-2024 | Freestyle Libre 3 |
| Pfizer INC. | $106.80 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.96 | 2021-2024 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $61.86 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.87 | 2019-2024 | |
| Amgen INC. | $36.46 | 2021-2022 | |
| Sanofi Pasteur INC. | $35.57 | 2020-2022 | |
| Shield Therapeutics INC | $34.64 | 2023-2025 | Accrufer |
| Boston Scientific Corporation | $24.60 | 2022 | |
| Vanda Pharmaceuticals INC. | $23.21 | 2019 | |
| Idorsia Pharmaceuticals US INC | $21.91 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $20.21 | 2021 | |
| Antares Pharma, INC. | $19.87 | 2022 | |
| Ironshore Pharmaceuticals INC. | $17.99 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $17.00 | 2022 | |
| Lilly USA, LLC | $16.70 | 2024 | Jardiance |
| Genentech USA, INC. | $16.37 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.08 | 2025 | Rexulti |
| Esperion Therapeutics, INC. | $13.18 | 2023 | Nexletol |
| Exact Sciences Corporation | $13.07 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $13.04 | 2023 | Shingrix, Bexsero, Pediarix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Calderon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.